Viera Kosmálová, Viera Husárová, Eva Hirnerová, Ján Lietava
Components of metabolic syndrome as abdominal obesity and/or insulin resistance could hamper a hypotensive effect of antihypertensive medication. We evaluated interaction of several markers of cardiometabolic risk with hypotensive effect of short-term therapy with nitrendipine in 3015 patients (39.8 % males and 60.2 % females) aged 61.8±11.6 years (19-95 years) with moderate to severe arterial hypertension. Out-ward patients with arterial hypertension exhibited high prevalence of metabolic syndrome - 48.3 % with significant prevalence in females 53.7 % vs. 40.2 %. Short-lasting therapy with nitrendipine caused important decrease of blood pressure and significant reduction of absolute risk according to SCORE about 36.2 % Overweight, obesity, abdominal obesity, hypertriglyceridemic waist, metabolic syndrome or diabetes mellitus did not exhibit negative impact on effectiveness of nitrendipine.